Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hysterectomy | 2 | 2022 | 86 | 0.740 |
Why?
|
| Dysmenorrhea | 1 | 2021 | 2 | 0.720 |
Why?
|
| Endometriosis | 1 | 2021 | 19 | 0.710 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 50 | 0.710 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 58 | 0.670 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 304 | 0.580 |
Why?
|
| Child Mortality | 1 | 2016 | 4 | 0.510 |
Why?
|
| Cause of Death | 1 | 2016 | 73 | 0.500 |
Why?
|
| Hospital Mortality | 1 | 2016 | 159 | 0.480 |
Why?
|
| Cost-Benefit Analysis | 4 | 2022 | 115 | 0.440 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2021 | 18 | 0.400 |
Why?
|
| Female | 8 | 2022 | 15624 | 0.210 |
Why?
|
| Adolescent | 3 | 2021 | 3193 | 0.200 |
Why?
|
| Endometrial Hyperplasia | 1 | 2022 | 6 | 0.190 |
Why?
|
| United States | 4 | 2022 | 2222 | 0.190 |
Why?
|
| Oncologists | 1 | 2022 | 15 | 0.190 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 46 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 347 | 0.180 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2021 | 1 | 0.180 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2021 | 35 | 0.180 |
Why?
|
| Macaca mulatta | 1 | 2021 | 50 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 78 | 0.170 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2020 | 5 | 0.170 |
Why?
|
| Trastuzumab | 1 | 2020 | 12 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 33 | 0.160 |
Why?
|
| Endometrial Neoplasms | 1 | 2022 | 189 | 0.160 |
Why?
|
| Ethanol | 1 | 2021 | 125 | 0.160 |
Why?
|
| Adult | 3 | 2021 | 8024 | 0.160 |
Why?
|
| Middle Aged | 2 | 2021 | 7414 | 0.160 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 80 | 0.160 |
Why?
|
| Body Mass Index | 1 | 2021 | 412 | 0.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 136 | 0.160 |
Why?
|
| Cohort Studies | 1 | 2021 | 897 | 0.150 |
Why?
|
| Humans | 8 | 2022 | 28851 | 0.150 |
Why?
|
| Quality of Life | 1 | 2021 | 521 | 0.130 |
Why?
|
| Hematometra | 1 | 2016 | 1 | 0.130 |
Why?
|
| Dilatation and Curettage | 1 | 2016 | 4 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2021 | 634 | 0.130 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 36 | 0.130 |
Why?
|
| Ethiopia | 1 | 2016 | 9 | 0.130 |
Why?
|
| Uterus | 1 | 2016 | 31 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2016 | 35 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 433 | 0.130 |
Why?
|
| Hospitals, Pediatric | 1 | 2016 | 31 | 0.130 |
Why?
|
| Developing Countries | 1 | 2016 | 49 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 122 | 0.120 |
Why?
|
| Young Adult | 1 | 2021 | 2833 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2016 | 916 | 0.100 |
Why?
|
| Infant | 1 | 2016 | 1025 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2016 | 1173 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2011 | 13 | 0.090 |
Why?
|
| Competency-Based Education | 1 | 2011 | 18 | 0.090 |
Why?
|
| General Surgery | 1 | 2011 | 63 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 149 | 0.080 |
Why?
|
| Child | 1 | 2016 | 2287 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2016 | 2635 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2011 | 250 | 0.070 |
Why?
|
| Male | 2 | 2016 | 13921 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2022 | 108 | 0.040 |
Why?
|
| Fetal Development | 1 | 2021 | 26 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 16 | 0.040 |
Why?
|
| Placenta | 1 | 2021 | 78 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 33 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 121 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 200 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 480 | 0.040 |
Why?
|
| Pregnancy | 1 | 2021 | 1254 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 17 | 0.030 |
Why?
|
| Vomiting | 1 | 2016 | 14 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1507 | 0.030 |
Why?
|
| Program Development | 1 | 2011 | 87 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 117 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 174 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 2426 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2011 | 235 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 303 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 995 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 997 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 10684 | 0.020 |
Why?
|